Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14325455 | 0.83 | LMNA (0.44) | MCL1LMNAKMT2ARECQLALDH1A1 | |
| SCHEMBL10071348 | 0.80 | EGLN1 (0.43) | MCL1LMNAKMT2ARECQLALDH1A1 | |
| SCHEMBL17640820 | 0.79 | RECQL (0.52) | LMNAKMT2ARECQL | |
| SCHEMBL2106440 | 0.78 | — | — | |
| SCHEMBL10131957 | 0.77 | CA1 (0.38) | RECQLALDH1A1TDP1 | |
| SCHEMBL19155815 | 0.76 | RECQL (0.46) | LMNAKMT2ARECQLALDH1A1TDP1 | |
| SCHEMBL260075 | 0.75 | — | — | |
| SCHEMBL19061397 | 0.75 | LMNA (0.33) | LMNARECQLALDH1A1TDP1 | |
| SCHEMBL21440852 | 0.75 | CA1 (0.37) | RECQLALDH1A1TDP1 | |
| SCHEMBL20887524 | 0.75 | CA1 (0.37) | RECQLALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648315-B2 | Silvestrol antibody-drug conjugates and methods of use | GENENTECH, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20200222545-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2020-07-16 | — | — | US | disclosed |
| US-10639378-B2 | Silvestrol antibody-drug conjugates and methods of use | GENENTECH, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20180125995-A1 | ANTI-STAPHYLOCOCCUS AUREUS ANTIBODY RIFAMYCIN CONJUGATES AND USES THEREOF | GENENTECH, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180021450-A1 | ANTI-STAPHYLOCOCCUS AUREUS ANTIBODY RIFAMYCIN CONJUGATES AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| WO-2017214024-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170348422-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348422-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | SHBG, EPCAM, ITGAV | MCL1 1449/4885LMNA 2820/4885KMT2A 503/4885 |
| US-20200222545-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | SHBG, EPCAM, ITGAV | MCL1 1449/4885LMNA 2820/4885KMT2A 503/4885 |
| US-11648315-B2 | Silvestrol antibody-drug conjugates and methods of use | SHBG, EPCAM, ITGAV | MCL1 1449/4885LMNA 2820/4885KMT2A 503/4885 |
| US-20180021450-A1 | ANTI-STAPHYLOCOCCUS AUREUS ANTIBODY RIFAMYCIN CONJUGATES AND USES THEREOF | RIF1, HDAC6, NRDC | MCL1 2630/4885LMNA 3361/4885KMT2A 2247/4885 |
| US-10639378-B2 | Silvestrol antibody-drug conjugates and methods of use | SHBG, EPCAM, ITGAV | MCL1 1449/4885LMNA 2820/4885KMT2A 503/4885 |
| US-20180125995-A1 | ANTI-STAPHYLOCOCCUS AUREUS ANTIBODY RIFAMYCIN CONJUGATES AND USES THEREOF | RIF1, AFF1, RFT1 | MCL1 1941/4885LMNA 3502/4885KMT2A 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.